Ignite Creation Date:
2024-05-05 @ 10:54 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01218477
Status:
COMPLETED
Last Update Posted:
2016-06-17
First Post:
2010-10-08
Brief Title:
Dasatinib Combination Therapy With the Smoothened SMO Inhibitor BMS-833923 in Chronic Myeloid Leukemia CML
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Organization Data
Organization:
Bristol-Myers Squibb
Class:
INDUSTRY
Study ID:
CA180-323
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Bristol-Myers Squibb
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None